AlphAIAlphAI — Financial news for AI agents
marketscreener.comOCT 151 min read

Goldman Sachs Adjusts Price Target on Incyte to $117 From $118

Goldman Sachs lowered its price target for Incyte from $118 to $117. The stock is currently trading at $111.57, with a 5-day change of +2.72% and a year-to-date change of -1.65%. Truist also raised its target to $115 from $105, maintaining a Hold rating.

Original reporting
marketscreener.com
Published Oct 15, 2026, 10:37 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 15, 2026, 10:50 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
MARKET
Neutral
AI market analysis
Mentioned
$INCY
Relevance
4/10
AlphAI data visualization · based on marketscreener.com
Decision brief

The 30-second read

Low
01

Why it matters

A slight target reduction may lead to modest share price adjustment.

02

Market read

Small analyst target change with limited trading impact.

03

What to watch

Recent trial data or partnership news not mentioned could offset the target reduction.

Relevance 4/10Novelty 3/10Timing: pre-market today

Background

Goldman Sachs regularly updates price targets based on its valuation models.

Market effects

Sector

Minimal impact on biotech sector; similar target adjustments may follow.

Regional

Negligible regional effect.

Global

Low global relevance.

Counterpoint

What could challenge this read

Target cut may be overly cautious; upside could remain if pipeline progresses.

Key entities

  • analyst
    Goldman Sachs

    Equity research firm issuing the target change.

  • company
    Incyte

    Biopharmaceutical company whose target was adjusted.

Read at source← All news

Related articles

OCT 13
Med

HC Wainwright & Co. reiterates Buy rating on Incyte, $152 price target

HC Wainwright & Co. reiterated a Buy rating on Incyte (INCY) with a $152 price target, suggesting a 36.5% upside from the Oct 12 close. The firm cited strong pipeline potential, particularly for drug INCB161734, with a 69% response rate in untreated patients and projected annual sales of $700 million in the U.S. G12D pancreatic cancer market.

tradingview.com1 min
OCT 13
$SNDXHighAI 8/10

Syndax shares fall as lung fibrosis drug fails trial

Syndax Pharma's shares fell 17% pre-market after abandoning its IPF drug axatilimab, which failed a phase 2 trial. The drug, partnered with Incyte, is approved for cGVHD as Niktimvo. Incyte's shares also dipped slightly. Syndax reported $152M in 2025 revenue, with $115M in the first half of 2026.

pharmaphorum.com2 min
OCT 7
$INCYMed

Incyte (INCY) Won New Approvals, Is The Pullback A Cheap Entry?

Incyte (INCY) received U.S. approval for Atebrioz and Brazil's expedited approval for NIKTIMVO. Shares are down 6.52% in 7 days and 10.50% in 30 days, but up 11.85% year-to-date and 32.86% in 1 year. The stock trades 14% below the average analyst price target. Incyte's 2026 guidance projects total net sales of $5.13B-$5.26B and Opzelura net sales of $1.05B-$1.10B. Analysts value the stock at $128.48, while a DCF model values it at $93.58.

simplywall.st2 min